Hillmen, Peter <br/><br/>
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.  [electronic resource] 

 -  British journal of haematology  Mar 2011 
 - 570-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2010.08317.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Mitoxantrone--administration & dosage<br/>Neoplasm, Residual<br/>Rituximab<br/>Survival Analysis<br/>Treatment Outcome<br/>Vidarabine--administration & dosage